DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
Olmutinib is an investigational drug.
There have been 7 clinical trials for Olmutinib. The most recent clinical trial was a Phase 2 trial, which was initiated on July 17th 2017.
The most common disease conditions in clinical trials are Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, and [disabled in preview]. The leading clinical trial sponsors are Hanmi Pharmaceutical Company Limited, Boehringer Ingelheim, and Konkuk University Medical Center.
There are twenty-five US patents protecting this investigational drug and two hundred and twenty-six international patents.
Recent Clinical Trials for Olmutinib
|Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI||Hanmi Pharmaceutical Company Limited||Phase 1|
|Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA||Hanmi Pharmaceutical Company Limited||Phase 2|
|Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA||Konkuk University Medical Center||Phase 2|
Top disease conditions for Olmutinib
Top clinical trial sponsors for Olmutinib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Olmutinib||⤷ Sign up for a Free Trial||Method for preparing thienopyrimidine compound and intermediates used therein||HANMI PHARM. CO., LTD. (Hwaseong-si, KR)||⤷ Sign up for a Free Trial|
|Olmutinib||⤷ Sign up for a Free Trial||Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases||ZHEJIANG DTRM BIOPHARMA CO. LTD. (Hangzhou, CN)||⤷ Sign up for a Free Trial|
|Olmutinib||⤷ Sign up for a Free Trial||Combinations for the treatment of neoplasms using quiescent cell targeting with EGFR inhibitors||Felicitex Therapeutics, Inc. (Natick, MA)||⤷ Sign up for a Free Trial|
|Olmutinib||⤷ Sign up for a Free Trial||Process for preparing thienopyrimidine compound and intermediates used therein||HANMI PHARM. CO., LTD. (Hwaseongi-si, KR)||⤷ Sign up for a Free Trial|
|Olmutinib||⤷ Sign up for a Free Trial||Bifunctional molecules for degradation of EGFR and methods of use||Dana-Farber Cancer Institute, Inc. (Boston, MA)||⤷ Sign up for a Free Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Olmutinib||China||CN107108649||2034-12-30||⤷ Sign up for a Free Trial|
|Olmutinib||European Patent Office||EP3224257||2034-12-30||⤷ Sign up for a Free Trial|
|Olmutinib||Spain||ES2759795||2034-12-30||⤷ Sign up for a Free Trial|
|Olmutinib||Japan||JP2018502081||2034-12-30||⤷ Sign up for a Free Trial|
|Olmutinib||South Korea||KR101803499||2034-12-30||⤷ Sign up for a Free Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|